<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213885</url>
  </required_header>
  <id_info>
    <org_study_id>PXL330-001</org_study_id>
    <nct_id>NCT04213885</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position</brief_title>
  <official_title>Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking With Corneal Thinning Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Specialists of Indiana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye Specialists of Indiana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the Peschke PXL-330 is safe and effective in the treatment of corneal&#xD;
      thinning conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, infectious keratitis,&#xD;
      or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on&#xD;
      corneal crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy&#xD;
      delivery. Patients will undergo monitoring for 1 year, with serial measurements of corneal&#xD;
      topography, visual acuity, intraocular pressure and visual function questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2029</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Treatment of patients with disease</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Randomized at outset</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean keratometry in diopters</measure>
    <time_frame>1 year</time_frame>
    <description>Average keratometry across the anterior topography of the cornea computed by a validated Scheimpflug topographer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of best corrected visual acuity on the validated early-treatment diabetic retinopathy study scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Keratoconus, Unstable</condition>
  <condition>Ectasia Corneal</condition>
  <condition>Bacterial Keratitis</condition>
  <arm_group>
    <arm_group_label>Pulsed Accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mW, 5 sec, 5 sec off, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9mW continuous, 10 minutes of illumination. Combination Product: PXL-330 Platinum device for cross linking with Peschke riboflavin solution will be used to load the cornea followed by UV-A cross linking of the cornea</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PXL 330 Platinum device/Riboflavin</intervention_name>
    <description>30mW, 5 sec, 5 sec off, 10 minutes of illumination</description>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_label>Pulsed Accelerated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Criterion 1,2,3 are required for all participants. Participants must&#xD;
        also meet one or more of criteria 4-12. Criteria 13 is only relevant for contact lens&#xD;
        wearers.&#xD;
&#xD;
          1. 12 years of age or older&#xD;
&#xD;
          2. Signed written informed consent&#xD;
&#xD;
          3. Willingness and ability to comply with schedule for follow-up visits&#xD;
&#xD;
          4. Presence of central or inferior steepening&#xD;
&#xD;
          5. Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid&#xD;
             marginal degeneration&#xD;
&#xD;
          6. Presence of one or more findings associated with keratoconus or pellucid marginal&#xD;
             degeneration, such as&#xD;
&#xD;
               1. Fleisher ring&#xD;
&#xD;
               2. Vogt's striae&#xD;
&#xD;
               3. Decentered corneal apex&#xD;
&#xD;
               4. Munson's sign&#xD;
&#xD;
               5. Rizzutti's sign&#xD;
&#xD;
               6. Apical corneal scarring consistent with Bowman's breaks&#xD;
&#xD;
               7. Scissoring of the retinoscopic reflex&#xD;
&#xD;
               8. Crab-claw appearance on topography&#xD;
&#xD;
          7. Steepest keratometry (Kmax) value greater than or equal to 47.2&#xD;
&#xD;
          8. I-S keratometry difference &lt; 1.5 D on the Pentacam map or topography map&#xD;
&#xD;
          9. Posterior corneal elevation &gt; 16 microns&#xD;
&#xD;
         10. Thinnest corneal point &lt;485 microns&#xD;
&#xD;
         11. Predicted Post LASIK/PRK stromal ablation depth &lt;350 microns or expected keratometry&#xD;
             &gt;47.2, or patients undergoing PRK/SMILE in keratoconus suspect eyes&#xD;
&#xD;
         12. Bacterial or fungal keratitis persistent and not responding despite &gt; 2 weeks of&#xD;
             standard antimicrobial therapy or with rapid progression of corneal thinning, with&#xD;
             loss of &gt;25% corneal thickness&#xD;
&#xD;
         13. Contact lens wearers only:&#xD;
&#xD;
               1. Removal of contact lenses for the require period of time prior to the screening&#xD;
                  refraction:&#xD;
&#xD;
        Contact Lens Type Discontinuations Time: Soft, 1 week; Soft Extended Wear, 2 weeks; Soft&#xD;
        Toric, 3 weeks; Rigid Gas Permeable, 2 weeks per decade of wear -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Eyes classified as normal or atypical normal on the severity grading scheme&#xD;
&#xD;
          2. Corneal pachymetry at the screening exam that is &lt;300 microns at the the thinnest&#xD;
             point in the eye(s) to be treated.&#xD;
&#xD;
          3. Previous ocular condition (other than refractive error) in the eye(s) to be treated&#xD;
             that may predispose the eye for future complications, for example:&#xD;
&#xD;
               1. History of or active corneal disease (e.g. herpes simplex, herpes zoster&#xD;
                  keratitis, recurrent erosion syndrome, acanthamoeba, etc.)&#xD;
&#xD;
               2. Clinically significant corneal scarring the CXL treatment zone that is not&#xD;
                  related to keratoconus or, in the investigator's opinion, will interfere with the&#xD;
                  cross-linking procedure.&#xD;
&#xD;
          4. Pregnancy (including plan to become pregnant) or lactation during the course of the&#xD;
             study&#xD;
&#xD;
          5. A known sensitivity to the study medications&#xD;
&#xD;
          6. Patients with nystagmus or any other condition that would prevent a steady gaze during&#xD;
             the CXL treatment of diagnostic tests.&#xD;
&#xD;
          7. Patients with a current condition that, in the physician's opinion, wold interfere&#xD;
             with or prolong epithelial healing.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clark L Springs, MD</last_name>
    <phone>317-925-2200</phone>
    <email>csprings@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Glenn Kirk, OD</last_name>
    <phone>317-925-2200</phone>
    <email>gkirk@esicare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye Specialists of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clark L Springs, MD</last_name>
      <phone>317-925-2200</phone>
      <email>csprings@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Glenn Kirk, OD</last_name>
      <phone>317-925-2200</phone>
      <email>gkirk@esicare.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

